EWU Institutional Repository

Marketing Feasibility Study of Ambrisentan

Show simple item record

dc.contributor.author Haider, Md. Rafiqul
dc.date.accessioned 2019-02-26T09:46:52Z
dc.date.available 2019-02-26T09:46:52Z
dc.date.issued 12/23/2009
dc.identifier.uri http://dspace.ewubd.edu/handle/2525/2963
dc.description This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh. en_US
dc.description.abstract Objective: The purpose of this study to examine the efficacy and safety doses of ambrisentan in patient with pulmonary arterial hypertension. Background: Pulmonary arterial hypertension is a life threatening and progressive diseases with limited treatment option. Endothelin is a vasoconstrictor and smooth muscle cell mitogen (that plays critical role in the pathogens and progression of P AH. Methods: In this regard the writer uses different methods collection of data from different sources. The writer uses books, journal, internet, company visits (RENET A) for IMS data Result: There are five drugs available in the international market for the treatment of P AH. By comprising all the drugs it is found that Ambrisentan is better than all others. Conclusion: Ambrisentan appears to improve exercise capacity, symptom, and hem dynamics in patients with pulmonary arterial hypertension . The incidence and severity of liver enzyme abnormalities appears to low. en_US
dc.language.iso en_US en_US
dc.publisher East West University en_US
dc.relation.ispartofseries ;PHA00047
dc.subject Feasibility Study of Ambrisentan en_US
dc.title Marketing Feasibility Study of Ambrisentan en_US
dc.type Thesis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account